Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
PEL will explore the PLI scheme and apply if its beneficial.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company will review FDA's response and decide on appropriate next steps soon.
Subscribe To Our Newsletter & Stay Updated
